Paradigm Completes Upsized $14M Placement Ahead of Phase 3 Interim Analysis
Paradigm Biopharmaceuticals completes upsized $14 million placement ahead of Phase 3 interim analysis
Paradigm Biopharmaceuticals (ASX: PAR) has completed a $14 million placement to institutional and sophisticated investors, significantly exceeding the initial $8 million target due to strong investor demand. The company has also launched a Share Purchase Plan (SPP) to raise up to an additional $2 million on the same terms, allowing eligible shareholders to participate in the capital raising.
The placement was priced at $0.19 per share, representing a 15.6% discount to the last traded price of $0.225. A total of 73,684,211 new fully paid ordinary shares were issued under the company’s existing placement capacity. Following completion of the placement and anticipated drawdowns under the company’s convertible note facility, Paradigm’s pro forma cash position is expected to be approximately $45 million, excluding SPP proceeds and any potential option exercise proceeds.
The funds are intended to extend the company’s runway through the upcoming interim analysis of its Phase 3 PARAOA012 trial, which is evaluating injectable pentosan polysulfate sodium (iPPS) for moderate-to-severe knee osteoarthritis. The interim analysis is expected in Q3 CY2026, with 100% patient dosing targeted for Q2 CY2026.
Paul Rennie, Managing Director
“The strong demand for the Placement, resulting in it being significantly upsized, reflects growing investor confidence in Paradigm’s Phase 3 program and the upcoming interim analysis. This capital raising positions the Company to continue executing our global Phase 3 clinical trial through key data milestones, including interim analysis. We believe this is a critical period for the Company as we approach a major value inflection point.”
When big ASX news breaks, our subscribers know first
What is an interim analysis and why does it matter for clinical trials?
An interim analysis is a pre-planned review of trial data conducted before a clinical study completes. In the case of Paradigm’s Phase 3 trial, an independent Data Safety Monitoring Board (DSMB) will review unblinded data to assess both safety and early efficacy signals when approximately 50% of participants have reached the primary endpoint at Day 112.
There are three potential outcomes from the interim analysis. The DSMB may recommend the trial continue as planned, which indicates the data are consistent with the pre-defined statistical framework and supports continuation to final analysis. Alternatively, the DSMB may identify early efficacy—a statistically significant treatment effect exceeding the pre-defined boundary—which could support expedited regulatory pathways. The downside case is futility, where the observed effect falls below the pre-defined threshold and does not support progression to New Drug Application (NDA) submission.
For investors, the interim analysis represents a near-term catalyst that could provide an early read on the probability of success at final readout without waiting for full trial completion. A positive outcome could accelerate partnering discussions and potentially trigger strategic optionality, whilst a futility finding would require program reassessment. This milestone is particularly significant as it will provide visibility on the likelihood of achieving regulatory approval and commercial launch, both of which are critical to the company’s valuation.
Phase 3 trial progress and upcoming clinical milestones
The Phase 3 PARAOA012 trial has dosed more than 50% of the targeted 466 patients, with 100% dosing expected in Q2 CY2026. The randomised, placebo-controlled trial is evaluating injectable pentosan polysulfate sodium (iPPS) for moderate-to-severe knee osteoarthritis, with patients receiving 2 mg/kg subcutaneously twice weekly for six weeks.
Recruitment is progressing across multiple geographies. The United States remains the primary contributor to enrolment, with an established site network driving consistent patient flow. Hong Kong has demonstrated rapid ramp-up following site activation, with approximately 55 patients screened in the first week and a low screen failure rate. Australia continues to contribute through 15 active sites, delivering a high-quality patient population aligned with inclusion criteria. Moldova is expected to activate imminently, adding incremental capacity to support the final recruitment push.
The primary endpoint is change in average daily pain at Day 112, measured using a numerical rating scale. Key secondary endpoints include WOMAC pain and function scores, Patient Global Impression of Change (PGIC), and structural imaging biomarkers assessed via MRI and X-ray.
Upcoming clinical milestones:
- DSMB review of safety data from 20% of participants dosed – Q2 CY2026
- 100% recruitment (~466 patients enrolled and commence treatment) – Q2 CY2026
- Sufficient participants reach Day 112 for interim analysis – Q3 CY2026
- Independent DSMB review of data (interim analysis) – Q3 CY2026
- Primary endpoint top-line readout – Q1 CY2027
This milestone density provides multiple potential re-rating catalysts over the coming months, with recruitment momentum supporting confidence in the stated timeline.
Use of funds and capital structure flexibility
The $14 million raised will be allocated across four key areas. $8.4 million has been earmarked for global Phase 3 clinical trial costs, supporting continued trial execution through the interim analysis and into the post-interim period. A further $2.0 million will fund NDA-related activities, including regulatory submission preparation. $2.1 million will be applied to partial repayment of the company’s Obsidian Convertible Note Facility, reducing reliance on future drawdowns. The remaining $1.5 million covers working capital and costs associated with the capital raising.
| Use of Funds | Allocation (A$m) |
|---|---|
| Global Phase 3 clinical trial (PARA_OA_012) | $8.4 |
| NDA-related activities | $2.0 |
| Partial repayment of Obsidian Convertible Note Facility | $2.1 |
| Working capital and costs of capital raising | $1.5 |
| Total | $14.0 |
The partial repayment of the Obsidian facility enhances overall capital structure flexibility and reduces the company’s dependence on convertible debt. Current forecasts indicate funding extends through to the end of CY2026, excluding any proceeds from the exercise of attaching options. This positions the company to reach the interim analysis without requiring additional dilutive funding under the current plan.
Attaching options provide additional funding pathway
For every one new share subscribed under the placement and SPP, the company will issue one attaching option, subject to shareholder approval at an Extraordinary General Meeting expected in early June 2026. The attaching options are exercisable at $0.2375, representing a 25% premium to the placement price. They expire on the earlier of 1 December 2026 or 20 business days following announcement of interim analysis results.
Upon exercise of an attaching option, holders will receive one piggyback option exercisable at $0.38 (a 100% premium to the placement price), with expiry on 30 April 2029. The company intends to apply for quotation of both the attaching options and piggyback options on the ASX, subject to meeting applicable listing requirements.
If all attaching options are exercised, the company could receive up to approximately $52 million in additional funding. The option structure is designed to align shareholder and company interests around clinical success, with the expiry linked to the interim analysis accelerating capital inflows in the event of a positive outcome.
The osteoarthritis market opportunity
Osteoarthritis affects approximately 528 million people globally, with projections indicating the number could approach 1 billion by 2050 as populations age and obesity rates rise. Knee osteoarthritis accounts for around 69% of all osteoarthritis cases, representing the largest single segment of the disease burden.
Despite the scale of the affected population, there are currently no approved disease-modifying therapies available. Existing treatments are largely symptom-focused, including analgesics, anti-inflammatory medications and surgical interventions such as joint replacement. According to published data, 81% of osteoarthritis patients report dissatisfaction with current treatment options, highlighting significant unmet medical need.
The economic burden is substantial. In the United States alone, annual healthcare expenditure on osteoarthritis exceeds $70 billion, with the total economic burden—including indirect costs such as lost productivity—exceeding $300 billion. If Paradigm’s iPPS achieves regulatory approval and demonstrates clinical efficacy, it would be entering a multi-billion dollar commercial opportunity with limited effective competition in the disease-modifying segment.
The next major ASX story will hit our subscribers first
Indicative timetable and next steps
Key dates for investors tracking the capital raising completion and option issuance are outlined below:
- Settlement of Placement Shares: 30 April 2026
- Allotment and Quotation of Placement Shares: 1 May 2026
- SPP Offer Opens: 4 May 2026
- SPP Offer Closes: 26 May 2026
- Announcement of SPP Results: 1 June 2026
- Allotment and Quotation of SPP Shares: 2 June 2026
- Extraordinary General Meeting (EGM) for shareholder approval of attaching options: Expected early June 2026
- Allotment and Quotation of Attaching Options: Expected early June 2026
The timetable is indicative and subject to change in accordance with ASX Listing Rules and the Corporations Act 2001.
The company has stated its intention to seek non-dilutive funding from a partnering or regional licensing arrangement following a successful interim analysis. Such a transaction would materially extend runway and reduce future dilution risk, positioning Paradigm to advance towards NDA submission and potential commercialisation without further equity capital requirements under the current plan.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Get real-time alerts on clinical trial results, FDA approvals, and market-moving announcements the moment they break. Click the “Free Alerts” button at Big News Blast to stay ahead on biotech developments.